

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 25 and under (MA review of TA554) [ID6290]

#### Draft stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Novartis (tisagenlecleucel)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>African Caribbean Leukaemia Trust</li> <li>Anthony Nolan</li> <li>Black Health Agency</li> <li>Blood Cancer UK</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> <li>Cancer52</li> <li>Childhood Cancer Parents Alliance</li> <li>Children with Cancer</li> <li>Children’s Cancer and Leukaemia Group</li> <li>DKMS</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Kevin Kararwa Leukaemia Trust</li> <li>Leukaemia Cancer Society</li> <li>Leukaemia CARE</li> <li>Macmillan Cancer Support</li> <li>Maggie’s Centres</li> <li>Marie Curie</li> <li>Solving Kids Cancer</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Teenage Cancer Trust</li> <li>Tenovus Cancer Care</li> <li>Young Lives vs Cancer</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Cancer Physicians</li> <li>British Blood Transfusion Society</li> <li>British Committee for Standards in Haematology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>AAH Pharmaceuticals Ltd (dasatinib, imatinib)</li> <li>Accord Healthcare Ltd (cytarabine, filgrastim, fludarabine, imatinib, pegfilgrastim)</li> <li>Alliance Healthcare Ltd (cytarabine)</li> <li>Amarox Ltd (imatinib)</li> <li>Amgen Ltd (blinatumomab, filgrastim, pegfilgrastim)</li> <li>Bristol-Myers Squibb Pharmaceutical Limited (dasatinib)</li> <li>Chugai Pharma UK Ltd (lenograstim)</li> <li>Consilient Health Ltd (clofarabine)</li> </ul>

Draft stakeholder list for the technology appraisal of tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 25 and under (MA review of TA554) [ID6290].

Issue date: July 2023

© National Institute for Health and Care Excellence 2013. All rights reserved.

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics &amp; Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK CLL Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Dr. Reddy's Laboratories (UK) Ltd (imatinib)</li> <li>• Esteve Pharmaceuticals Ltd (imatinib)</li> <li>• Incyte BioSciences UK Ltd (ponatinib)</li> <li>• Napp Pharmaceuticals Ltd (pegfilgrastim)</li> <li>• Novartis Pharmaceuticals Ltd (imatinib)</li> <li>• Pfizer Ltd (cytarabine, filgrastim, idarubicin, inotuzumab ozogamicin)</li> <li>• Sandoz Ltd (filgrastim, imatinib, pegfilgrastim)</li> <li>• Sanofi (fludarabine)</li> <li>• Teva Pharma B.V. (lipegfilgrastim, dasatinib, fludarabine, imatinib)</li> <li>• Tillomed Laboratories Ltd (clofarabine)</li> <li>• Viatrix UK Healthcare Ltd (dasatinib)</li> <li>• Zentiva Pharma Ltd (dasatinib, imatinib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Cochrane UK</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia Busters</li> <li>• Leukaemia UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Draft stakeholder list for the technology appraisal of tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 25 and under (MA review of TA554) [ID6290].

Issue date: July 2023

© National Institute for Health and Care Excellence 2013. All rights reserved.

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.